CN106497949A - 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 - Google Patents
一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 Download PDFInfo
- Publication number
- CN106497949A CN106497949A CN201610898732.6A CN201610898732A CN106497949A CN 106497949 A CN106497949 A CN 106497949A CN 201610898732 A CN201610898732 A CN 201610898732A CN 106497949 A CN106497949 A CN 106497949A
- Authority
- CN
- China
- Prior art keywords
- plasma thromboplastin
- high activity
- thromboplastin component
- mutain
- activity plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022641 Coagulation factor IX Human genes 0.000 title claims abstract description 61
- 108010076282 Factor IX Proteins 0.000 title claims abstract description 57
- 230000000694 effects Effects 0.000 title claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 11
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 6
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 6
- 238000001415 gene therapy Methods 0.000 claims abstract description 11
- 102200052251 rs199469629 Human genes 0.000 claims abstract description 11
- 239000013598 vector Substances 0.000 claims abstract description 10
- 239000012679 serum free medium Substances 0.000 claims abstract description 7
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- 230000006698 induction Effects 0.000 claims abstract description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 3
- 239000003114 blood coagulation factor Substances 0.000 claims abstract description 3
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 208000032843 Hemorrhage Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000009429 hemophilia B Diseases 0.000 claims description 5
- 101000823435 Homo sapiens Coagulation factor IX Proteins 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 230000001475 anti-trypsic effect Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 101710081722 Antitrypsin Proteins 0.000 claims 1
- 229940019700 blood coagulation factors Drugs 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract description 9
- 229940105774 coagulation factor ix Drugs 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 4
- 229960004222 factor ix Drugs 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 238000009256 replacement therapy Methods 0.000 abstract description 3
- 206010053567 Coagulopathies Diseases 0.000 abstract description 2
- 230000035602 clotting Effects 0.000 abstract description 2
- 101150108210 IX gene Proteins 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 8
- 102200063714 rs137852283 Human genes 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 102220643581 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1_R338L_mutation Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 1
- 101150039948 F9 gene Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 101000880344 Homo sapiens Elongation factor G, mitochondrial Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 101150042441 K gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- -1 calcium chloride saccharide Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108010013935 factor IX-Padua Proteins 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310336787.8A CN116355883A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
CN202310417526.9A CN116732066A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
CN201610898732.6A CN106497949A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610898732.6A CN106497949A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310336787.8A Division CN116355883A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
CN202310417526.9A Division CN116732066A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106497949A true CN106497949A (zh) | 2017-03-15 |
Family
ID=58294253
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610898732.6A Pending CN106497949A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
CN202310336787.8A Pending CN116355883A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
CN202310417526.9A Pending CN116732066A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310336787.8A Pending CN116355883A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
CN202310417526.9A Pending CN116732066A (zh) | 2016-10-14 | 2016-10-14 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN106497949A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439679A (zh) * | 2018-10-09 | 2019-03-08 | 上海市儿童医院 | 一种高活性重组人凝血因子ix融合蛋白及其制备方法 |
US10413598B2 (en) | 2014-11-12 | 2019-09-17 | Ucl Business Plc | Factor IX gene therapy |
GB2576508A (en) * | 2018-08-20 | 2020-02-26 | Ucl Business Plc | Factor IX encoding nucleotides |
WO2020039183A1 (en) * | 2018-08-20 | 2020-02-27 | Ucl Business Plc | Factor ix encoding nucleotides |
CN110945127A (zh) * | 2017-05-22 | 2020-03-31 | 百深公司 | 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体 |
JP2022159358A (ja) * | 2017-05-31 | 2022-10-17 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 最適化されたヒト凝固第ix因子遺伝子発現カセットおよびそれらの使用 |
US11517631B2 (en) | 2018-08-20 | 2022-12-06 | Ucl Business Ltd | Factor IX encoding nucleotides |
CN117126832A (zh) * | 2023-10-26 | 2023-11-28 | 四川维亚本苑生物科技有限公司 | 一种重组人凝血因子ix融合蛋白及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010029178A1 (en) * | 2008-09-15 | 2010-03-18 | Paolo Simioni | Factor ix polypeptide mutant, its uses and a method for its production |
CN103282491A (zh) * | 2010-11-03 | 2013-09-04 | 催化剂生物科学公司 | 修饰的因子ix多肽及其用途 |
-
2016
- 2016-10-14 CN CN201610898732.6A patent/CN106497949A/zh active Pending
- 2016-10-14 CN CN202310336787.8A patent/CN116355883A/zh active Pending
- 2016-10-14 CN CN202310417526.9A patent/CN116732066A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010029178A1 (en) * | 2008-09-15 | 2010-03-18 | Paolo Simioni | Factor ix polypeptide mutant, its uses and a method for its production |
CN103282491A (zh) * | 2010-11-03 | 2013-09-04 | 催化剂生物科学公司 | 修饰的因子ix多肽及其用途 |
Non-Patent Citations (1)
Title |
---|
AKASH MATHUR ET AL.: "protease and egf1 domains of factor ixa play distinct roles in binding to factor viiia", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10413598B2 (en) | 2014-11-12 | 2019-09-17 | Ucl Business Plc | Factor IX gene therapy |
US11344608B2 (en) | 2014-11-12 | 2022-05-31 | Ucl Business Ltd | Factor IX gene therapy |
CN110945127A (zh) * | 2017-05-22 | 2020-03-31 | 百深公司 | 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体 |
JP2022159358A (ja) * | 2017-05-31 | 2022-10-17 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 最適化されたヒト凝固第ix因子遺伝子発現カセットおよびそれらの使用 |
GB2576508A (en) * | 2018-08-20 | 2020-02-26 | Ucl Business Plc | Factor IX encoding nucleotides |
WO2020039183A1 (en) * | 2018-08-20 | 2020-02-27 | Ucl Business Plc | Factor ix encoding nucleotides |
US11517631B2 (en) | 2018-08-20 | 2022-12-06 | Ucl Business Ltd | Factor IX encoding nucleotides |
CN109439679A (zh) * | 2018-10-09 | 2019-03-08 | 上海市儿童医院 | 一种高活性重组人凝血因子ix融合蛋白及其制备方法 |
CN117126832A (zh) * | 2023-10-26 | 2023-11-28 | 四川维亚本苑生物科技有限公司 | 一种重组人凝血因子ix融合蛋白及其制备方法 |
CN117126832B (zh) * | 2023-10-26 | 2024-01-30 | 四川维亚本苑生物科技有限公司 | 一种重组人凝血因子ix融合蛋白及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN116732066A (zh) | 2023-09-12 |
CN116355883A (zh) | 2023-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106497949A (zh) | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 | |
JP6947888B2 (ja) | クロストリジウム・ヒストリチクム(clostridium histolyticum)酵素およびその使用のための方法 | |
DK2337849T3 (en) | FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF | |
WO2019114324A1 (zh) | 一种高活性凝血因子xi突变体及其基因治疗/编辑载体、重组/融合蛋白的制备与应用 | |
JP4705026B2 (ja) | 血管内皮増殖促進遺伝子 | |
GB2144428A (en) | Heat treatment of plasma | |
EP4212623A1 (en) | High-activity blood coagulation factor xi mutant ala570thr | |
CN104231073A (zh) | 一种人凝血因子viii的制备方法 | |
CN107929719B (zh) | 一种冻干人血浆活化凝血因子vii浓制剂的大规模生产制备方法 | |
JP2012503477A (ja) | ヒャッポダ由来のヘモコアグラーゼ | |
JP2024023297A (ja) | 可溶化アピラーゼ、方法及び使用 | |
DK147408B (da) | Fremgangsmaade til udvinding af thrombinagtige enzymer fra slangegifte eller slangegiftfraktioner | |
Meng et al. | A deep sequencing reveals significant diversity among dominant variants and evolutionary dynamics of avian leukosis viruses in two infectious ecosystems | |
US3434929A (en) | Process for purifying plasmin | |
WO1998030230A1 (fr) | Compositions proteinees et procede de production | |
Nakamura et al. | L-Asparaginase from E. coli Part I. Crystallization and Properties | |
JP2008517585A (ja) | 組換え型プロトロンビン活性化プロテアーゼ(rLOPAP)を単量体の形態で取得するための方法;組換え型プロトロンビン活性化プロテアーゼ(rLOPAP)及びそのアミノ酸配列;デフィブリノゲナーゼ剤としての該プロテアーゼの使用および異常プロトロンビン血症のための診断キット | |
CN109260462B (zh) | 一种凝血酶原突变体蛋白及其编码核酸的应用 | |
Hussain et al. | Preparation of Water Insoluble Thrombin. | |
TWI541252B (zh) | 因子vii/viia之量產方法 | |
CN102719439A (zh) | 一种突变型人表皮生长因子基因、蛋白及其制备方法和应用 | |
RU2648517C1 (ru) | Способ получения лиофилизированного препарата активированного протромбинового комплекса, обладающего фактор viii-шунтирующей активностью | |
CN102719460A (zh) | 一种白眉蝮蛇类凝血酶基因及其应用 | |
RU2445974C2 (ru) | Способ получения концентрата фактора viii из плазмы крови человека | |
JP2004123566A (ja) | ヒト血漿由来血液凝固第xiii因子製剤およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200331 Address after: 610094 Chengdu Tianfu international biological city, Chengdu, Sichuan Province (No.18, Section 2, middle biological Road, Shuangliu District) Applicant after: Sichuan Zhishan Weixin Biotechnology Co.,Ltd. Address before: 200025 Huangpu District, Ruijin, No. two, No. 197 Road (Yongjia road junction), Shanghai Applicant before: RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG University SCHOOL OF MEDICINE Applicant before: SICHUAN University |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |